What is the main purpose of this 8-K filing?

This filing announces an extension of the expiration date for Bristol-Myers Squibb's (BMY) offers to exchange Celgene Corporation notes (Celgene Notes) for new BMY notes and cash, and for related solicitations of consents to amend the terms of the Celgene Notes. This is a procedural update tied to the ongoing acquisition of Celgene.

Why has the expiration date for the exchange offers and consent solicitations been extended?

The extension is to align with the expected timeline for the closing of Bristol-Myers Squibb's acquisition of Celgene. The offers are conditioned on the merger closing, and the new expiration date of October 15, 2019, reflects the anticipated closing by the end of 2019.

What are investors to make of this extension regarding the Celgene acquisition?

The extension suggests that the closing of the Celgene acquisition is still on track for the end of 2019 but may take a bit longer than initially planned. It indicates that BMY is managing the financial and legal aspects of the acquisition in parallel with finalizing the merger itself.

When will the exchange of Celgene Notes and the amendments take effect?

The exchange offers and consent solicitations are contingent upon the closing of the Celgene merger. Settlement is expected to occur promptly after the new expiration date (October 15, 2019) and on or about the date the merger officially closes.

BRISTOL MYERS SQUIBB CO 8-K SEC Disclosure

Summary

Bristol-Myers Squibb Company (BMY) has extended the expiration date for its offers to exchange Celgene Corporation notes (Celgene Notes) for new BMY notes and cash, as well as related consent solicitations to amend the terms of the Celgene Notes. The new expiration date is now October 15, 2019, pushed back from September 30, 2019. This extension is directly tied to the pending acquisition of Celgene by BMY and indicates that the closing of this significant merger is anticipated to occur by the end of 2019. Investors should note that the exchange offers and consent solicitations are contingent upon the successful closing of the Celgene merger, a condition that BMY cannot waive. The settlement of these offers is expected to happen promptly after the expiration date and around the time of the merger's closing. This filing provides an update on the timeline for these important transactions that will reshape BMY's debt structure and consolidate its acquisition of Celgene.

Key Highlights

1BMY extended the expiration date for its exchange offers and consent solicitations related to Celgene Notes to October 15, 2019.
2These offers are in connection with BMY's pending acquisition of Celgene.
3The exchange offers involve exchanging Celgene Notes for up to $19,850,000,000 aggregate principal amount of new BMY notes and cash.
4The consent solicitations aim to amend the terms of the Celgene Notes, removing restrictive covenants and certain default provisions.
5The closing of the Celgene merger is expected by the end of 2019, and the Exchange Offers/Consent Solicitations are conditioned on this closing.
6Settlement of the exchange offers and consent solicitations is anticipated to occur on or about the closing date of the merger.

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Sep 23, 2019)

Summary

Key Highlights

Frequently Asked Questions